Use of Rapamycin for Cognitive Optimization Among Patients with Alzheimer’s Disease and Dementia
Dr. Sheldon Jordan
MD, The Regenesis Project
Dr. Jordan specializes in advanced imaging techniques, interventions for brain and nerve injury, anti-aging of the brain, and regenerative medicine. As chief investigator for numerous institutional review board-approved clinical research projects, Dr. Jordan actively endeavors to advance the boundaries of neurological care.
Previous research has reported the beneficial effects of sirolimus (rapamycin) administration in numerous animal models of aging and neurodegeneration, including Alzheimer’s disease. To address a lack of clinical and patient-reported data, this Circle aims to evaluate the development of Alzheimer’s disease among patients partaking in a rapamycin treatment plan. Following the administration of rapamycin, patients will complete study assessments, including the Montreal Cognitive Assessment (MoCA) test and Quick Dementia Rating Scale (QDRS), on a quarterly basis for 12 months.
Interventional
- Montreal Cognitive Assessment (MoCA) Test - Version 8.1
- Quick Dementia Rating Scale (QDRS)
- Multidimensional Fatigue Inventory (MFI-20)
- Patient Health Questionnaire (PHQ-9)
- General Anxiety Disorder Questionnaire (GAD-7)
- Longitudinal, real-world safety and efficacy assessment of rapamycin prescription.
- Regular Circle hours discussing Dr. Jordan’s evidence-based analyses and protocols.
- Remote, turnkey, administration of the full MoCA assessment.
- Targeted, automated caregiver reminders for medication adherence and lab work.
Private
Use of Rapamycin for Cognitive Optimization Among Patients with Alzheimer’s Disease and Dementia
Previous research has reported the beneficial effects of sirolimus (rapamycin) administration in numerous animal models of aging and neurodegeneration, including Alzheimer’s disease. To address a lack of clinical and patient-reported data, this Circle aims to evaluate the development of Alzheimer’s disease among patients partaking in a rapamycin treatment plan. Following the administration of rapamycin, patients will complete study assessments, including the Montreal Cognitive Assessment (MoCA) test and Quick Dementia Rating Scale (QDRS), on a quarterly basis for 12 months.
Comparative MoCA scores at 6 and 12 months post-intervention for patient cohorts defined by type of medication or other therapy administered.
MoCA, QDRS, MFI-20, PHQ-9, GAD-7
Neurologists, psychiatrists, geriatricians, primary care physicians, and other clinicians.
- Longitudinal, real-world safety and efficacy assessment of rapamycin prescription.
- Regular Circle hours discussing Dr. Jordan’s evidence-based analyses and protocols.
- Remote, turnkey, administration of the full MoCA assessment.
- Targeted, automated caregiver reminders for medication adherence and lab work.
Streamlined patient enrollment, real-world data capturing, heightened recognition, prominence and collaboration
Private